Navigation Links
Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
Date:2/23/2009

BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assistant Professor, Divisions of Infectious Diseases and Organ Transplantation at Northwestern University Feinberg School of Medicine, during the XI International Symposium on Respiratory Viral Infections taking place in Bangkok, Thailand, February 19 through February 22, 2009. This exploratory Phase 2 trial compared the efficacy and safety of five days of therapy with either 200 mg intravenous (i.v.) peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice-a-day, in patients who required hospitalization related to influenza.

The primary objective of the study was to evaluate time to clinical stability, which is a composite endpoint comprised of normalization of temperature, oxygen saturation, respiratory rate, systolic blood pressure and heart rate. This type of endpoint has previously been used in pneumonia studies, but not in influenza. Secondary objectives of the study included evaluation of viral shedding, mortality, clinical relapse and time to resumption of usual activities. The primary efficacy population was defined as patients with confirmed influenza.

As reported in October 2008, there were no statistically significant differences in any of the efficacy endpoints between the three treatment arms, and peramivir was generally safe and well-tolerated at these dose levels. Evaluation of time to clinical stability, the primary endpoint, showed a median of 23.7 hours for peramivir 200 mg, 37.0 hours for peramivir 400 mg and 28.1 hours for oseltamivir (p=0.306). This exploratory endpoint was driven b
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
4. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
5. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
6. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
9. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... -- Sigma-Aldrich Corporation (NASDAQ: SIAL ... company, today announced the opening of its ... Cell Culture Technical Center in Singapore.  Located at ... support to meet customer needs, leveraging the Company,s ... Technical Center will significantly enhance our ability to ...
(Date:4/16/2015)... -- A drug commonly taken to prevent seizures in epilepsy ... (MS), according to a study released today that will be ... in Washington, DC , April 18 to ... MS experience at some point in their life a condition ... from the eye to the brain gets inflamed," said study ...
(Date:4/16/2015)... , April 16, 2015 Today, Kenneth C. ... & Co., Inc., was elected chairman of the Board of ... Board meeting, PhRMA,s president and CEO John J. Castellani ... 2016.  New Officers Elected to PhRMA Board ... succeeds Ian C. Read , chairman and CEO of ...
Breaking Medicine Technology:Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5Epilepsy Drug May Preserve Eyesight for People with MS 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... April 17, 2015 Testosterone treatment ... class of prescription medications increases the likelihood that ... or other life-threatening cardiovascular event continue to mount ... Court, Northern District of Illinois. According to an ... Panel on Multidistrict Litigation (JPML) on April 15th, ...
(Date:4/17/2015)... Connie Casad, M.D., a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... for her patients with the availability of a reader’s ... with a brief synopsis on each for her patients. ... providing this service, Dr. Casad said, “Furnishing a researched ...
(Date:4/17/2015)... has released a new blog post explaining the dangers of ... insurance rates . , Falling asleep at the wheel ... big impact on auto insurance prices. The premiums will go ... The newly released blog post talks more about drowsiness at ... It is now possible to find low cost car insurance ...
(Date:4/17/2015)... April 17, 2015 According to the ... estimated 50 million Americans suffer from all types of ... and eye allergies. Thanks to comprehensive allergy testing that’s ... caremedurgentcare.com ), there’s now a way to get recommended ... , “Allergy triggers, or allergens, can vary by region ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 3
... , WEDNESDAY, May 25 (HealthDay News) -- This ... "Don,t Fry Day," a time for skin-safety experts to remind ... Melanoma, the potentially deadly form of skin cancer, is the ... according to the U.S. Environmental Protection Agency (EPA) and the ...
... the FASEB Journal ( http://www.fasebj.org ) shows that ... maximizing the effects of exercise. Specifically, the report shows that ... six weeks, when compared to carbohydrate drinks. Additionally, this study ... as 20 grams of protein. "It is ...
... less-than-optimal levels of vitamin D who lose more than 15 ... levels of this fat-soluble nutrient, according to a new study ... vitamin D is generally lower in persons with obesity, it ... for the link between obesity and diseases such as cancer, ...
... As the use of oral chemotherapy continues to rise, researchers ... properly take the cancer-fighting medication, a significant clinical problem that ... of adherence needs to be addressed by the health care ... the study that is published in the May edition of ...
... WEDNESDAY, May 25 (HealthDay News) -- Science has shown that ... mice to monkeys live longer. But can such a ... those extra years be healthy, happy ones? Recent research ... calorie intake have lower core body temperatures than those who ...
... announced an agreement with two non-profit organizations to ... rare blood cancers. The cooperative research and ... commitment to move therapies for rare blood cancers ... can eventually be commercialized. The agreement is among ...
Cached Medicine News:Health News:Skin Cancer Foes Declare May 27 'Don't Fry Day' 2Health News:Protein drinks after exercise help maintain aging muscles 2Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 2Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 3Health News:Many patients fail to properly take oral chemo, leading to complications 2Health News:Could 'Extreme' Low-Cal Diets Bring Longer, Healthier Life? 2Health News:Could 'Extreme' Low-Cal Diets Bring Longer, Healthier Life? 3Health News:NIH and non-profits sign research and development agreement 2
... standards set by the new SZ61 and ... "Comfort View eyepiece design and the accessible, ... fatiguing than ever before. The compact design ... field as well as clarity, detail, and ...
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility....
10:1 Zoom Ratio - The parallel optical system of the SMZ-1000 has a 10:1 zoom with clickstops at 1X intervals. It features a zoom range of 0.8X to 8.0X and total magnification (depending on eyepieces...
Medicine Products: